NCT05019040View on ClinicalTrials.gov

Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 17, 2021

Primary Completion Date

November 15, 2022

Study Completion Date

November 18, 2022

Conditions
Chronic HBV Infection
Interventions
DRUG

PA1010

TDF as control

Trial Locations (4)

400010

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

Unknown

Beijing Tsinghua Changgung Hospital affiliated to Tsinghua, Beijing

Southern Hospital of Southern Medical University, Guangzhou

The First Affiliated Hospital of Medical College of Zhejiang University, Hangzhou

All Listed Sponsors
lead

Zhejiang Palo Alto Pharmaceuticals, Inc.

INDUSTRY

NCT05019040 - Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients | Biotech Hunter | Biotech Hunter